Dickson Bbuye

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

Anna Turkova, Ellen White, Cissy Kityo et al. · UCL Discovery (University College London) · 2021 · 103 citations

Pharmacy, Pediatrics, Pharmacotherapy +16

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Pauline Amuge, Abbas Lugemwa, Ben Wynne et al. · The Lancet HIV · 2022 · 31 citations · Full text

Pharmacy, Infectious Diseases, Pediatrics +15

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Anna Turkova, Hylke Waalewijn, Man K. Chan et al. · The Lancet HIV · 2022 · 24 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

Alexandra Compagnucci, Man K. Chan, Yacine Saïdi et al. · EClinicalMedicine · 2023 · 16 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Pretreatment HIV drug resistance predicts accumulation of new mutations in ART‐naïve Ugandan children

Sandra Soeria‐Atmadja, Pauline Amuge, Sarah Nanzigu et al. · Acta Paediatrica · 2020 · 13 citations · Full text

Public Health, Child Health, Pediatrics +17